Aeva (AEVAW) Form 144 — Proposed 200k Common Share Sale Disclosed
Rhea-AI Filing Summary
Aeva Technologies, Inc. (AEVAW) Form 144 discloses a proposed sale of 200,000 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $2,756,000. The filing lists 56,327,698 shares outstanding and records the 200,000 shares as founders' shares acquired on 12/05/2016.
The notice also reports recent sales in 2025: 69,901 shares sold on 07/07/2025 for $2,134,077.53 by Soroush Salehian Dardashti, and 250,000 shares sold on 05/19/2025 under a 10b5-1 plan for $3,924,650. The filer affirms no material nonpublic information and references Rule 10b5-1 procedures.
Positive
- Transparent disclosure of a proposed sale of 200,000 common shares through Morgan Stanley Smith Barney LLC, including acquisition details (founders' shares).
Negative
- Insider disposition planned: proposed sale of 200,000 common shares is recorded against 56,327,698 shares outstanding.
- Recent insider liquidity in 2025 includes sales of 250,000 shares (10b5-1, gross proceeds $3,924,650) and 69,901 shares (gross proceeds $2,134,077.53), all disclosed in the filing.
Insights
Founder intends to sell 200,000 common shares; prior 250,000 and 69,901-share sales occurred in 2025.
The Form 144 specifies a proposed disposition of 200,000 common shares via Morgan Stanley Smith Barney LLC with aggregate market value $2,756,000. The filing shows these are founders' shares acquired on 12/05/2016 and confirms 56,327,698 shares outstanding. Recent reported dispositions in 2025 include a 250,000 share 10b5-1 sale and a 69,901 share sale, both disclosed with gross proceeds. For investors, this is a factual record of insider liquidity rather than new operating information.
Rule 144 notice and 10b5-1 reference show ongoing insider liquidity with explicit transaction details and broker disclosure.
The filing provides concrete compliance elements: broker identification (Morgan Stanley Smith Barney LLC), acquisition history (founders' shares dated 12/05/2016), and prior sales including a 10b5-1 plan. The signer represents no undisclosed material adverse information. These disclosures meet Rule 144 reporting expectations and document insider disposals; they do not by themselves indicate corporate governance changes.